Patent Costs (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Jun. 30, 2025 |
Jun. 30, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Finite-Lived Intangible Assets [Line Items] | ||||||
| Legal fees | $ 711,148 | $ 701,089 | ||||
| Accumulated amortization | $ 80,000 | 80,000 | $ 74,667 | $ 58,667 | ||
| Estimated useful lives | 5 years | |||||
| Amortization expenses | 139,022 | 69,877 | $ 162,568 | 107,830 | ||
| Patents [Member] | ||||||
| Finite-Lived Intangible Assets [Line Items] | ||||||
| Legal fees | 701,089 | 515,402 | ||||
| Accumulated amortization | $ 55,510 | $ 55,510 | $ 6,920 | $ 3,182 | ||
| Estimated useful lives | 14 years | 14 years | 15 years | 15 years | ||
| Amortization expenses | $ 7,152 | $ 794 | $ 48,590 | $ 1,587 | $ 3,738 | $ 3,182 |
| X | ||||||||||
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|